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Abstract
The field of probiotics is up-and-coming, especially in management of microbial 
pathogens. Probiotics confer nutritional benefits, reduce inflammation and infec-
tion. Probiotics have also shown to be helpful in the management of microbial 
pathogens, which include bacteria, fungi, and viruses. To ernes this potential 
maximumly, there is a need for an elaborate screening system for new isolates. This 
entails; rigorous screening methods and thorough confirmatory systems. There 
is need also to come up with standard methods used to evaluate the probiotics 
mechanism of action both in vivo and in vitro. In summary, there is a need for a 
standard screening process for probiotic microorganisms that is reproducible. The 
aim is to ensure that, the candidate microbial cultures are not written off without 
proper investigations. This will also fasten the screening process and save time and 
resources wasted in pre-screening experiments.
Keywords: probiotics, screening methods, confirmatory methods, postbiotics, 
animal model, coculture
1. Introduction
Fermentation is one of the oldest technologies used for food preservation. 
It involves converting carbohydrates to alcohol, carbon dioxide, and organic 
acids using microorganisms under anaerobic conditions. The fermentation pro-
cess improves food by developing diverse flavors, aromas, and textures in food 
substrates. Also, it enriches food substrates with protein, essential amino acids, 
essential fatty acids, and vitamins. The primary mechanism of the preservation 
of foods is the production of acid, which lowers the pH to a level at which most of 
the spoilage-causing microorganisms cannot grow, hence prolonging the shelf life 
of such foods [1]. At present, various fermented foods are produced worldwide at 
household and industrial levels, in both small-scale and large commercial enter-
prises. Associated with fermentation are beneficial microorganisms known as 
probiotics. The vast majority of the probiotics are lactic acid microorganisms [2] to 
produce fermented dairy products.
Among the beneficial effects of probiotics include improved intestinal health, 
enhancement of the immune response, reduction of serum cholesterol, and cancer 
prevention [3–5]. There is also substantial evidence to support probiotic use in 
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treating acute diarrhoeal diseases, prevention of antibiotic-associated diarrhea, 
and improvement of lactose metabolism [6]. The range of food products contain-
ing probiotic strains is vast and still growing. And so is the list of beneficial effects. 
More so, with an increasing desire for quality life, preference for minimal use of 
chemicals, and the rising cost of healthcare. Natural products like probiotics is a 
promising alternative. Related to probiotics are prebiotics. Biogenics involves the 
use of beneficial bioactive substances produced by probiotic bacteria whose activi-
ties are independent of the viability of probiotic bacteria.
This book chapter focuses on the use of probiotics in the management of micro-
bial pathogens, emphasizing the need to have a reproducible standard screening 
process both in vivo and in vitro. This will highlight areas in the used technologies 
that need harmonization, technologies for investigation and confirmation of the 
antimicrobial activities of probiotics, and finally, the future prospects of probiotics 
and antimicrobial agents.
1.1 Mechanism of action of probiotics
WHO/FAO defines probiotics as “live microorganisms that, when administered 
in adequate amounts, confer a health benefit on the host” [7, 8]. Prebiotics refer 
to the substrates that are selectively utilized by host microorganisms that result in 
conferring a health benefit to the host [8–11]. Furthermore, postbiotics entails the 
use of beneficial bioactive compounds produced by probiotic bacteria. The activity 
of postbiotics is independent of probiotic bacteria’s viability [11]. The term synbiot-
ics is where both prebiotics and probiotics are utilized simultaneously [11, 12].
The probiotics have myriad of mechanisms in which it protects against infection. 
These include; (1) they lower pH, (2) pathogen antagonism by producing antimi-
crobial compounds for example, bacteriocins and or other metabolic products, (3) 
competitive exclusion with the pathogen for binding sites and receptors sites, (4) 
competition for substrates that is, nutrients and growth factors, therefore, limit-
ing resources, (5) stimulate immunomodulatory cells, (6) production of enzymes 
example, enzymes that neutralize toxins produced by pathogens (7) improve the 
barrier function of the intestinal mucosa, (8) modulate inflammatory responses, 
(9) aggregate with pathogens, (10) produce hydrogen peroxide (H2O2) a strong 
oxidizing agent that damage nucleic acids and proteins, (11) produce organic acids 
like lactic acid, acetic acid among others (12) produce CO2 thus creating anaerobic 
microenvironment (Figure 1) [3, 4, 13–16].
The probiotics are generally regarded as safe [17]. The few results obtained when 
probiotics are administered together with conventional drugs clinically are promis-
ing and include synergy with the drug, half dose of conventional drug needed, and 
faster healing [18–21]. Further research is needed in this area.
1.2 Probiotics as antimicrobial agents
Besides the health-improving benefits, the antimicrobial activity of probiotics 
has been well documented, with promising results against microbial pathogens. 
Probiotics have been deemed as the following most crucial immune defense systems 
according to WHO [7]. This is due to increasing antibiotic resistance to commonly 
prescribed antibiotics [22, 23]. There is a need, therefore, to come up with repro-
ducible screening protocols for in vitro, in vivo, and clinical studies. Therefore, this 
book chapter will highlight protocols used in screening probiotics and postbiotics, 
cite their strengths and drawbacks, and point areas that need harmonization.
3
Probiotics and Postbiotics from Food to Health: Antimicrobial Experimental Confirmation
DOI: http://dx.doi.org/10.5772/intechopen.99675
2. Areas in the used technology that need harmonization
To obtain reproducible and conclusive results of probiotic antimicrobial activity, 
standardization of protocols is essential. This section reviews the essential areas that 
will inform on the choice of indicator pathogen, probiotic microorganism, inocu-
lum size, incubation time and conditions, and technique of production of postbiot-
ics (also referred to as cell-free supernatant (CFS)/ Biogenic/spent media) used in 
previous research and the need for harmonization.
2.1 The selection of experimental indicator pathogen
The choice has relied on the target disease that the probiotic is thought to treat. 
Thus, for vulvovaginal candidiasis C. albicans, the predominant pathogen has been 
chosen [24, 25], even though Candida glabrata has also been screened [26, 27]. 
Enterotoxigenic E. coli and Salmonella typhimurium is the choice for studying 
gastrointestinal infection [28]. However, while screening new probiotic microor-
ganisms for general antimicrobial activity, major classes of pathogens of medical 
importance should be representatively tested [29]. For example, studies on fungal 
pathogens should include at least a dermatophyte, non-dermatophyte, and yeast. 
Antibacterial should consist of a Gram-positive and a Gram-negative bacterial 
pathogen. Furthermore, clinical, typed microorganism and drug-resistant strains 
should be included due to emerging resistance [10].
Figure 1. 
Mechanisms in which probiotics protect against infection.
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2.2 The choice of probiotic microorganism and postbiotics
The WHO/FAO has listed the criteria for evaluation of probiotic microorgan-
ism, which include; the ability of the microorganism to adhere to epithelial cells, 
bile salts, resist stomach acid and enzymes, persistence within the system, produce 
antimicrobial compounds, antibiotic resistance profile inability to confer resistance 
or genome stability and ability to stabilize the normal microbiota among others 
[7, 15, 30]. Probiotic antimicrobial activity is strain-specific; therefore, the species 
level and strain of the selected probiotic should be identified.
2.3 Inoculum size
The actual number of viable indicator pathogens in the inoculum size directly 
influences the outcome. Too little may lead to false-positive results, while too heavy 
inoculum may give a false negative result [29, 31]. A foundation for the inoculum 
size can be suggested by CLSI [32]. Researchers have used different inoculum size, 
incubation temperature, and time for both probiotic and indicator pathogen in in 
vitro, in vivo and clinical studies [9]. We propose that the viability and dose of pro-
biotic microorganisms used (also in the production of postbiotics) be established by 
dose-dependent experiments. This should be indicated in experimental reports.
2.4 The experimental conditions and incubation time
Lactic acid bacteria and Bifidobacteria are fastidious; subsequently, the media 
chosen should have a specific nutrient requirement, for example, growth factors. 
MRS, which is an appropriate media for the growth of probiotic microorganisms, 
is widely used. MRS is both a selective and an enriched media for the growth and 
isolation of only lactic acid bacteria and other bacteria. Therefore, if this medium 
cannot support the indicator pathogen, for example, dermatophytes (J. [33]), 
probiotic growth factors can be incorporated in any media of choice such as potato 
dextrose agar (PDA), sabouraud dextrose agar (SDA) and nutrient agar (NA) to 
favor the growth of both the indicator pathogen and the probiotic microorganism. 
Proper choice of media and specific modifications is key to a successful experiment 
[33, 34]. Therefore, media supplemented with growth factors should be screened 
for the ability to grow both probiotic microorganisms and indicator pathogen. We 
propose that the specific incubation conditions such as time and oxygen require-
ments for both probiotic microorganisms and indicator pathogen be optimized 
before the experiment and confirmed by the growth curve of individual microor-
ganisms (Figure 2). Furthermore, fresh media should always be prepared and used 
for reproductive results, especially in the case of disc diffusion results.
2.5 The technique of production of postbiotics
The postbiotics is also referred to as cell-free supernatant (CFS) or biogenics 
or spent media. The preparation of postbiotics is varied and attests to the need to 
harmonize the methods. The process entails the following steps; the probiotic micro-
organism is inoculated in broth media and incubated in an incushaker [35]. Cells are 
then removed by centrifuging to obtain the CFS ([36]; J. [33, 35, 37]). The supernatant 
obtained can then be screened for antimicrobial activity [35], or the supernatant is 
further filter-sterilized [35, 36]. The CFS is then used to screen for the microbial activ-
ity or concentrated to obtain concentrated CFS (cCFS) [38] [36] or freeze-dried [36].
The advantage of using postbiotics is that the properties of the active compo-
nent can be deduced. To ascertain if the active ingredient is proteinaceous, heat 
treatment and enzymes are used. If the activity is reduced or is lost compared 
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to non-treated postbiotic, it infers that the antimicrobial agent is proteinaceous 
[33, 38]. To ascertain if the antimicrobial activity is pH-related, the postbiotic is 
neutralized and buffered [30].
Figure 2. 
Detailed proposed method for conclusively screening probiotic antimicrobial activity. Step 1 entails choice of 
optimal media and growth conditions, step 2 is the preliminary screening on agar and step 3 is the confirmation 
of probiotic antimicrobial activity in liquid cocultures.
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3.  Technology for investigation and confirmation of the antimicrobial 
activity of probiotics
3.1  Experiments for investigation of antimicrobial potential of probiotics In vitro
Included in this section are the In vitro antagonism methods on agar plates and 
liquid coculture for checking probiotic antimicrobial activity with their strengths and 
drawbacks. In antagonism on agar plate’s methods, probiotic and indicator microor-
ganism is introduced in the same plate. The difference is the sequence and manner of 
the inoculation of either indicator pathogen or probiotic microorganisms. After incu-
bation, the diameter zone of inhibition which is the clear zones around the inoculated 
area, is then read in millimeters or reported or arbitrary units (AU) (Figures 2 and 3).
3.1.1 Antagonism on agar plate methods
3.1.1.1 Simple spot-on lawn assay
To screen postbiotics or probiotic microorganism using this method, the indi-
cator pathogen is first inoculated, then probiotic microorganisms are spotted at 
specific points on solid media [37]. Modification to the method entails spotting 
probiotic microorganisms as parallel lines [33]. Its strength includes (a) media can 
be modified [33, 34], (b) it has an option of different incubation conditions, i.e., 
probiotic microorganism incubation conditions are first optimized, followed by 
optimizations for indicator pathogen.
3.1.1.2 Spot on agar assay
Probiotic microorganisms are first spotted on agar media and then incubated 
[39]. An indicator pathogen is added, and soft agar at around 45–50°C is poured to 
Figure 3. 
Abridgement of methods involved in screening probiotic microorganisms both In vitro and In vivo.  
(a) In vitro preliminary screening experiments on agar. (b) In vitro confirmatory experiments. (c) In vivo 
animal confirmatory experiment. (d) In vivo clinical confirmatory experiment.
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the previously prepared plate spotted with a probiotic microorganism [25, 35]. The 
advantage of the Agar spot test is that two different media can be used, one for spot-
ting and the other as overlaid soft agar. Indicator and probiotic microorganisms can 
be grown at different times, meaning incubation conditions can be adjusted for each 
microorganism. The disadvantage is the high temperature of soft agar, i.e., between 
45°C and 50°C, killing heat-labile indicator microorganisms. The strict aerobes may 
not grow well due to the pour plate method.
3.1.1.3  Spot on lawn assay with wells also referred to as Agar well diffusion assay 
or as conventional whole plate method
The wells are dug and indicator pathogen inoculated. Then postbiotic/Probiotic 
is dispensed [37, 40]. Unlike the simple spot-on lawn assay method, the probiotic 
microorganism can be allowed to grow first before introducing the indicator micro-
organisms or vice versa.
3.1.1.4 Paper disc assay
The postbiotic/probiotic is dispensed on the paper discs and placed on the 
inoculated media. The inoculation of both indicator pathogen and probiotic micro-
organism is simultaneous. The disadvantage of this method is that the results are 
not reproducible [41]. This is mainly attributed to the production of non-diffusible 
antimicrobials.
3.1.1.5 Cross streak on agar assay
Entails streaking the probiotic microorganism as parallel lines on media. A 
perpendicular line of indicator pathogen is then streaked. Growth inhibition is 
determined at the interception point [40].
3.1.1.6 The radial streak on agar assay
The probiotic microorganism is inoculated as a circle in the middle of the agar 
plate. The indicator pathogen is then streaked as radial lines from the edge of the 
petri dish to the center, and growth inhibition is examined [42]. Another method 
closely related to this method is cutting the media with the probiotic microorgan-
isms and placing it on top of the indicator pathogen inoculated plate.
3.1.2 Liquid coculture method
The probiotic and indicator pathogens are both introduced to optimized broth 
culture media, then incubated. Samples are intermittently collected, and viability 
(cfu/ml) of indicator pathogen is established. It is used to determine if the probiotic 
effect is static or cidal [13, 24]. It may also be used to reveal the mechanism by which 
the probiotic bacteria exert their antimicrobial activity [35]. Microtitre assay is used 
to screen minimum inhibitory concentration (MIC) of postbiotics using microdilu-
tion method, macro serial dilution, or conventional kill time assay [35, 43]. Liquid 
coculture assay is recommended as a confirmatory test (Figures 2 and 3).
3.1.3 Summary of antagonism assay
Antagonism assay on agar plates has the advantage of being fast and straight-
forward. The disadvantage is that it does not directly interact with the probiotic 
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microorganism or postbiotics and indicator pathogen. Consequently, the probiotic 
microorganism should produce sufficient antimicrobial agent that should have the 
potential to diffuse through solid media in terms of size and spatial centrifugation 
[44]. Accordingly, it is not prudent to use these methods solely to ascertain antimi-
crobial activity of probiotic microorganisms. Hence, it is recommended to combine 
antagonism on agar plates and liquid coculture to establish the antimicrobial activ-
ity of probiotic microorganisms and postbiotics (Figures 2 and 3).
3.1.4 Cell culture and tissues
To closely mimic human infection, human cell cultures are infected with indica-
tor pathogen, then treated with probiotic cultures or postbiotics [41].
3.2 Experiments for the discovery of antimicrobial mechanisms of probiotics
The methods used to ascertain probiotic microorganism mechanisms of antimi-
crobial activity include; the ability to inhibit virulence factors and cell death.
3.2.1 Ability to inhibit virulence factors
The virulence factors of pathogenic microorganisms vary from one microorgan-
ism to the other. For example, the virulence factor in bacteria includes adhesion, 
immunoevasion and immunosuppression, exo-enzymes, and exotoxin, among 
others [45]. The virulent factors in Candida include secretion of hydrolases, yeast to 
hypha transition, contact sensing, thigmotropism, biofilm formation, phenotypic 
switching, and range of fitness attributes [27, 37]. The following methods can be 
used to examine the ability of the probiotic microorganism to inhibit the virulence 
factors;
3.2.1.1 Gene expression levels
The expression levels of specific genes controlling one or more of these virulence 
factors can be ascertained when checking for probiotic activity [14, 25, 35, 36, 
46–48]. The methods used include microarray analysis, RT-PCR techniques, and 
western blot [49].
3.2.1.2 Aggregation and coaggregation assay
Aggregation assay using spectrophotometric autoaggregation and coaggrega-
tion is used to ascertain the antimicrobial activity of probiotics [26, 38, 50]. The 
morphological transition of C. albicans that is, germ tube formation contributes 
to adherence and invasion to the host tissue and increases virulence [51, 52]. 
Lactobacilli build aggregates and co-aggregates with Candida cells, and this process 
neutralizes germ tube growth [53]. In addition, the coaggregation protects access 
of pathogens to a cell receptor and, as a result, inhibit pathogen adhesion which 
is a prerequisite step for colonization and the subsequent development of disease 
[26, 44, 50, 54].
3.2.1.3 Antibiofilm Assay
Biofilm produced by pathogens serves as a physical barrier and increases viru-
lence. Antibiofilm assay includes (a) static systems like microtiter plate, Molony 
biofilm, Calgary biofilm device, biofilm ring test (b) open systems such as Kadouri 
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system, flow cell, perfused (membrane) biofilm fermenter, microfermentors, 
Modified Robbins Device, sorbarod devices (SBF), drip flow reactor, constant 
depth film fermenter, microfluidic biochips, rotating disc reactor, BioFlux device, 
annular reactors, CDC biofilm reactors (c) microcosm example airway epithelial 
cell model, reconstituted human epithelia (RHE), endothelial cells under flow 
model, Zürich oral biofilm-model, microfluidic coculture model, Zürich burn 
biofilm-model, multiple Sorbarod devices (MSD) (d) ex-vivo which include; 
candidiasis in the vaginal mucosa, RWV bioreactor, cardiac valve ex vivo model, 
root canal biofilms [55]. Viable colonies can also be used. While fluorescent labeling 
of biofilm coupled with mathematical labeling is used [41].
3.2.1.4 Exo-enzymes
The indicator microorganisms are treated with probiotics or CFS. The indicator 
microorganism is then examined for the ability to produce exo-enzymes on agar 
plate assays. The agar plate contains a suitable substrate specific to each enzyme 
activity [56].
3.2.1.5 Electron microscopy
Scanning electron microscopy and Transmission electron microscope are used to 
examine cell integrity which includes morphological adherence, distortion, biofilm, 
or apoptosis [27, 50, 57].
3.2.1.6 Germ tube and hyphal growth inhibition
The pelleted spores of dermatophytes and dimorphic pathogenic fungus are 
allowed to develop germ tubes and hyphae. Probiotic or CFS is then added and incu-
bated. Growth is determined by examining germ tubes and hyphae [36, 58].
3.2.1.7 Spore germination inhibition assay
The pelleted mycelia and probiotic or CFS are added to media and incubated. 
Samples are withdrawn and microscopically examined. Percentage spore germina-
tion is calculated by the following formula [33, 36, 58]:
% spore germination = [Numbers of germinated spores /Numbers of total 
spores] × 100
3.2.1.8 Fluorescent metabolic dyes and Confocal laser scanning microscopy
The indicator microorganisms are treated with probiotic cultures or CFS then 
stained with fluorescent dyes according to the manufacturer’s instructions. The live 
or dead cells are counted, and their metabolic activity is ascertained [26, 27]. Live/
dead cells can also be confirmed by viable counts (cfu/ml).
3.2.2 Ability to induce cell death
A sequence of unique morphological changes outlines apoptosis. These include; 
visible cell shrinkage, extensive plasma membrane blebbing, chromatin condensa-
tion, nuclear fragmentation, formation of apoptotic bodies, which later undergoes 
decomposition within the phagosome and finally terminates with complete 
recycling of the components [59, 60]. Accumulation of reactive oxygen species 
(ROS) decreased membrane potential, biochemical and cytological responses well 
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known in programmed cell death (PCD), for instance, apoptosis [60]. Very high 
ROS concentrations induce necrosis [61]. These changes can be used to determine 
cell integrity. Of the biochemical and cytological methods used to check patho-
gen cell integrity after treatment with probiotics include but are not limited to; 
nuclear fragmentation using DAPI/Tunnel [62–67]; in situ ligation assay [65]; DNA 
laddering [65, 66]; externalization of Annexin V/PI by cell membrane [62, 64, 
67–70]; mitochondrial and cytosolic calcium [66, 67, 69, 71]; depolarization of the 
mitochondria using mitochondria membrane potential detection kits for instance, 
JC fluorescent probes [62, 63, 66–71]; reactive oxygen species (ROS) accumula-
tion [69] [66, 67, 70, 71]; detecting cytochrome c in cytoplasm using western 
blotting or color metric kits [63, 66–69, 71, 72]; cytosol / mitochondria intracel-
lular glutathione [67, 69]lipid peroxidation [67, 69]; potassium release [67] and 
metacaspace activation detection using kits like CaspACE FITC-VAD-FMK in situ 
Marker [63, 67–69]. The antimicrobial activity of a probiotic microorganism can be 
assessed using a combination of a number of these methods, which can corroborate 
the integrity of the indicator pathogen. Careful choice of positive (example, antimi-
crobial drug) and negative (untreated) controls are important for interpreting the 
results.
3.3 Experiments that confirm the antimicrobial activity of probiotics in vivo
The in vitro studies offer required information about antimicrobial agents on 
susceptibility responses [73], exposure times, and optimal concentrations [74]. 
However, these studies have their limitations, for instance, the bulk of antimicrobial 
agents that are active in vitro lack significant antimicrobial activity in vivo, and 
vice versa sometimes occurs [73]. The strength of animal models in determin-
ing antimicrobial efficacy is that the study can be ascertained at specific body 
sites, for example, skin, thigh, lung, peritoneum, meninges, and endocardia [74]. 
Furthermore, antimicrobial agents are altered by host factors such as metabolism 
and the immune system in an animal model [74]. Consequently, animal models 
bridge the gap between in vitro and clinical trials [73] and are indispensable for 
authentication of probiotic antimicrobial activity. In brief, in vivo animal models 
and clinical studies are an absolute requirement to provide proof of beneficial 
activities of probiotic antimicrobial activity. To achieve this, appropriate infectious 
models for the two groups are critical. One infected with indicator pathogen and 
treated with probiotic cultures, and the other group infected with indicator patho-
gen only (negative control).
3.3.1 In vivo experiments on animal models
The infection route of dermatophytes is strictly dependent on the goal of the 
study, indicator fungus, and animal disease model of interest. Examples, to study 
geophilic and anthrophilic dermatophytes; Microsporum gypseum and Trichophyton 
rubrum that is difficult to establish infections in laboratory animals’, zoophilic 
dermatophytes especially Trichophyton metangrophytes var. mentagrophtes, var. 
quinckeanum and var. granulae, Trichophyton verrucosum, and Microsporum canis are 
used instead. The most recommended animal model for dermatophytoses is hairless 
guinea pigs as the infection resembles infections in humans, and topical treatment 
is applicable. Mouse, rat, hamster, and dog are disadvantaged for dermatophytoses 
animal model since they defecate, lick, and bite itching or irritating lesions inten-
sively [75].
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C. albicans and Candida tropicalis have high virulence in systemically induced 
mice model [76–79]. Pregnant mice [75], zebrafish [80] and Caenorhabditis 
elegans [46] have also been utilized in disseminated systemic infection models. 
Candida metapsilosis is virulent in the vaginal mouse model [81]. Furthermore, 
oophectomised rats are used for chronic vaginitis [47, 75]. However, C. parapsilosis, 
C. glabrata, and C. krusei do not induce mice mortality [77]. Further, C. albicans 
[82], Ctropicalis, C. parapsilosis complex (C. parapsilosis, C. orthopsilosis, and C. 
metapsilosis), are virulent in the invertebrate Galleria monella model [77]. Induced 
immunosuppressed mice in murine oral candidiasis model of choice. To cause the 
immunosuppressed condition, administration of prednisolone 100 mg per kg [83] 
or ketamine: xylazine 90-100 mg/kg and 10 mg/kg respectively [84] of body weight 
administered by injected subcutaneously 24 h before inoculation with Candida 
orally is given. Additionally, avian and rats species can be used as oral candidiasis 
models [75, 84]; a summary of these in vivo models is given in Table 1.
Disease Animal Route of infection Target organ Reference
Dermatomycosis
Dermatomycosis Guinea pig Skin abrasion Skin localized 
infection
[75]











Bacterial and fungal 
systemic infection
Pregnant mice Intravascular placenta [75]





Injection systemic [20, 85]
Bacterial and fungal 
systemic infection













Vaginal swabs [47, 75]
Localized oral 
candidosis (thrush)







treatment and use of 
germ free or specific 
pathogen free 
animals
Mouth swabs [75, 84]
Table 1. 
Précis of in vivo animal models for dermatomycosis, candidiasis and bacterial infections.
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3.3.2 Clinical trials
Clinical trials are conducted after promising in vitro and in vivo animal model 
experiments. The randomized placebo-controlled clinical trial is the most recom-
mended method [10]. The number of clinical researches conducted on probiotics 
is about 1000, with Lactobacillus rhamnosus GG and B. animalis sp. Lactis being the 
most studied [41, 86]. The majority of these studies are on gastrointestinal diseases 
and the digestive system [86]. However, currently, there is a shift to metabolic 
disorders, communicable and infection [86]. The primary concerns in these clinical 
studies that need to be addressed for harmonization of probiotic clinical research 
include:
1. The probiotic dosage administered; only 42% of the clinical studies reported 
dosage correctly. It is recommended that the probiotic dosage is reported in 
colony-forming unit (CFU). Some clinical studies reported the number of 
drops, grams, or not indicated at all [86].
2. The amount of probiotic administered should be adequate [7, 87]; however, the 
amount used varied from 107 to 9 × 1011 per day [86].
3. The description of how the probiotic was prepared was incomplete in many 
studies [86].
4. Viability, which is the overall health of cells. It is crucial to check the viability 
of probiotics before administration and after a given duration since storage, 
transportation, and handling condition could kill some microorganisms.
5. It is essential to describe probiotic microorganisms not only to the species level 
but also to strain. This is because the diversity of probiotic microorganisms is 
enormous. Further, the probiotic activity is species and strain-specific  
[88–90]. This is incomplete in the majority of the clinical studies done. Only 
49% of the studies conducted complete strain identification.
6. Route, frequency, and duration [91] of probiotic administration should always 
be reported. Many studies omit this vital aspect.
7. Sample size affects the power of the study to draw a conclusion and the preci-
sion of estimates. Therefore, the sample size should be big enough to reduce 
bias, especially when some patients discontinue the study.
It is important to note that, these details including probiotic dosage used in clini-
cal studies, should be extrapolated from in vitro and in vivo models. Therefore, this 
emphasizes the importance of prior quality research.
Few clinical trials on confirmation of the antimicrobial effect of probiotics 
have been reported so far, yet they have been considered the final confirmative 
experiment. Probiotics are regarded as safe [13, 17]; thus, many researchers skip 
this critical step. This is the case in which many commercially marketed probiotics 
have pending clinical studies [92]. Probiotics clinical studies on the management of 
oral pathogens[9, 21, 93–95], urogenital infections [20, 96–99] and gastrointestinal 
systems [100] had promising results thus, supporting some probiotics as potential 
antimicrobial agents [10].
In conclusion, clinical studies are essential. Successful clinical studies require 
thorough in vitro and in vivo experiments, especially estimating the dosage, 
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duration, and frequency of probiotic administration. Areas that need urgent 
reporting and harmonization in clinical studies include probiotic viability, probiotic 
species and strain, dosage (CFU), duration, frequency of administration, and route 
of probiotics administration.
4. Summary and future prospects of probiotics as antimicrobial agents
The probiotics are offering a ray of hope to solve dwindling antibiotic efficacy. 
Further, the number of immunocompromised persons, number of microbial 
infections and drug resistance, and probiotics could come in handy to solve these 
problems. Therefore, there is a need for detailed conclusive research on in vitro, in 
vivo, and clinical trials of probiotic microorganisms, prebiotics, and postbiotics 
administration including, the benefits and side effects. The choice of probiotics, 
methods, and experimental designs need to be emphasized. Research has demon-
strated that probiotics of a particular strain may have antimicrobial activity against 
one pathogen and not another [9, 10, 14]. This has been attributed to the great 
diversity of virulence factors expressed by these pathogens. Some pathogens can 
produce exoenzymes, encode resistance genes, form biofilms, and induce inflam-
matory responses, among others [37, 101, 102]. The probiotic dosage, duration, 
frequency, formulation, viability, species-level, and strain, among others, should 
always be reported for conclusive studies. Otherwise, it would be pretty challeng-
ing to compare these experiments and draw a definite conclusion. Some particular 
probiotics do not show any antimicrobial activity in vitro but present significant 
activity in vivo and vice versa. Hence, there is a need for meticulous screening of 
probiotic microorganisms before the antimicrobial activity is or is not confirmed.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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